JP2019508481A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508481A5
JP2019508481A5 JP2018550872A JP2018550872A JP2019508481A5 JP 2019508481 A5 JP2019508481 A5 JP 2019508481A5 JP 2018550872 A JP2018550872 A JP 2018550872A JP 2018550872 A JP2018550872 A JP 2018550872A JP 2019508481 A5 JP2019508481 A5 JP 2019508481A5
Authority
JP
Japan
Prior art keywords
stap
pmo
stip
compound according
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018550872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508481A (ja
Filing date
Publication date
Priority claimed from GB1522548.5A external-priority patent/GB2545898B/en
Application filed filed Critical
Publication of JP2019508481A publication Critical patent/JP2019508481A/ja
Publication of JP2019508481A5 publication Critical patent/JP2019508481A5/ja
Priority to JP2023014917A priority Critical patent/JP2023055874A/ja
Pending legal-status Critical Current

Links

JP2018550872A 2015-12-21 2016-12-21 ステープルまたはステッチペプチドに複合された生物活性化合物 Pending JP2019508481A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023014917A JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1522548.5A GB2545898B (en) 2015-12-21 2015-12-21 Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB1522548.5 2015-12-21
PCT/GB2016/054028 WO2017109494A1 (en) 2015-12-21 2016-12-21 Biologically active compound conjugated to a stapled or stitched peptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023014917A Division JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Publications (2)

Publication Number Publication Date
JP2019508481A JP2019508481A (ja) 2019-03-28
JP2019508481A5 true JP2019508481A5 (enExample) 2022-06-16

Family

ID=55311362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018550872A Pending JP2019508481A (ja) 2015-12-21 2016-12-21 ステープルまたはステッチペプチドに複合された生物活性化合物
JP2023014917A Pending JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023014917A Pending JP2023055874A (ja) 2015-12-21 2023-02-02 ステープルまたはステッチペプチドに複合された生物活性化合物

Country Status (10)

Country Link
US (2) US11541124B2 (enExample)
EP (1) EP3393520A1 (enExample)
JP (2) JP2019508481A (enExample)
KR (1) KR20180091920A (enExample)
CN (1) CN108472385A (enExample)
AU (1) AU2016375869B2 (enExample)
BR (1) BR112018012641A2 (enExample)
CA (1) CA3007910A1 (enExample)
GB (1) GB2545898B (enExample)
WO (1) WO2017109494A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
GB2563875B (en) * 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN117567639A (zh) 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2020047399A1 (en) * 2018-08-31 2020-03-05 Massachusetts Institute Of Technology Ionizable lipidoids and their uses
AU2020258482B2 (en) * 2019-04-18 2026-02-12 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like E1-activating enzymes by structurally-stabilized peptides
KR102544364B1 (ko) * 2019-06-17 2023-06-19 주식회사 안단테에프엠 Romo1 유래 항균 펩타이드 및 그 변이체
KR102521182B1 (ko) * 2020-11-06 2023-04-12 서울대학교산학협력단 결핵균 독소-항독소 시스템을 표적으로 하는 항균 스테이플 펩타이드 및 이의 용도
WO2024069229A2 (en) 2022-08-03 2024-04-04 Sutura Therapeutics Ltd Biologically active compounds
WO2025027389A1 (en) 2023-08-03 2025-02-06 Sutura Therapeutics Limited Biologically active compounds comprising a stapled or stitched peptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003849A1 (en) * 1987-10-28 1989-05-05 Howard Florey Institute Of Experimental Physiology Oligonucleotide-polyamide conjugates
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
ES2639852T3 (es) * 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
WO2009149214A2 (en) 2008-06-03 2009-12-10 Aileron Therapeutics, Inc. Compositions and methods for enhancing cellular transport of biomolecules
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
EP2421971B1 (en) * 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
WO2011111874A1 (ja) 2010-03-11 2011-09-15 独立行政法人理化学研究所 細胞膜透過性ダンベル型rnaおよびその製造方法
CA2796722C (en) * 2010-04-19 2021-06-01 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CA3092114A1 (en) 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CN103998458B (zh) 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
CN103121959B (zh) 2011-11-21 2016-09-21 昆山市工业技术研究院小核酸生物技术研究所有限责任公司 化合物和核酸复合分子与核酸复合物及其制备方法和应用
WO2013150338A1 (en) * 2012-04-04 2013-10-10 Centre National De La Recherche Scientifique Stapled cell penetrating peptides for intracellular delivery of molecules
WO2014053879A1 (en) * 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
AU2013336582A1 (en) * 2012-10-26 2015-06-11 Nlife Therapeutics, S.L. Compositions and methods for selective delivery of oligonucleotide molecules to cell types
CN103626850B (zh) 2013-04-03 2015-08-26 安徽省新星药物开发有限责任公司 具有细胞穿透功能的多肽及其在药物递送中的用途
AU2016264471B2 (en) 2015-05-19 2022-01-27 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
MX384213B (es) 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
GB2545898B (en) 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
GB2563875B (en) 2017-06-28 2020-08-19 Sutura Therapeutics Ltd Improvements in drug delivery

Similar Documents

Publication Publication Date Title
US11944688B2 (en) Biologically active compounds
JP2019508481A5 (enExample)
US8575305B2 (en) Cell penetrating peptides
CA2846218C (en) Cell-penetrating peptides having a central hydrophobic domain
JP2023126866A (ja) 改善された薬物送達のためのステープル又はステッチペプチドを含む化合物
US20140140929A1 (en) Chemically modified cell-penetrating peptides for improved delivery of gene modulating compounds
JP2020525462A5 (ja) 改善された薬物送達のためのステープルされた又はステッチされたペプチドを含む化合物
KR102890965B1 (ko) 세포 투과 펩티드
KR20210109551A (ko) 링커
WO2024069229A2 (en) Biologically active compounds
GB2574525A (en) Improvements in drug delivery
GB2580569A (en) Improvements in drug delivery